MedPath

Ultrasound Beams as an Adjunct to Reperfusion Therapy in STEMI

Not Applicable
Conditions
Myocardial Infarction
ST Elevation Myocardial Infarction
Registration Number
NCT02299609
Lead Sponsor
Sakarya University
Brief Summary

Successfully perfused STEMI patients will receive routine transthoracic echocardiography qid for 4 days or placebo. Myocardial function and infarct size will be evaluated at 3 and 6 months.

Detailed Description

Patients who had acute STEMI and successfully reperfused by either thrombolytic therapy or primary angioplasty and stenting will be included this study.

A basal routine echocardiography will be obtained in all patients after reperfusion therapy. Thereafter, patients will be divided into two groups: 1.Treatment group will receive transthoracic echocardiography using Philips HD11 XE ® for 30 minutes qid for 4 days. 2. Placebo group will have the same Philips HD11 XE ® echo transducer applied for the same time and duration on their chest but with the ultrasound turned-off. Detailed left and right ventricle function as well as performance index and stress-strain imaging will be obtained and analyzed at 3 and 6 months.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Increase in left ventricular functionAt 3 and 6 months

Ultrasound beams during echocardiography application expected to ameliorate the left ventricle function

Secondary Outcome Measures
NameTimeMethod
Decrease in infarct sizeAt 3 and 6 months

Ultrasound beams during echocardiography application expected to decrease infarct size

Trial Locations

Locations (1)

Sakarya University, Faculty of Medicine

🇹🇷

Sakarya, Turkey

Sakarya University, Faculty of Medicine
🇹🇷Sakarya, Turkey
Ramazan Akdemir, MD
Contact
00905336020700
rakdemir@yahoo.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.